Immunosuppressants
K |
|||
| (2 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt) | |||
| Zeile 1: | Zeile 1: | ||
| + | {{up|PHA Biologicals}} | ||
'''Dapsone''' | '''Dapsone''' | ||
| Zeile 7: | Zeile 8: | ||
'''Cyclophosphamide''' | '''Cyclophosphamide''' | ||
{{tp|p=32526511|t=2020. A potential role for cyclophosphamide in the mitigation of acute respiratory distress syndrome among patients with SARS-CoV-2.|pdf=|usr=009}} | {{tp|p=32526511|t=2020. A potential role for cyclophosphamide in the mitigation of acute respiratory distress syndrome among patients with SARS-CoV-2.|pdf=|usr=009}} | ||
| + | |||
| + | |||
| + | '''Aminosalicylates''' | ||
| + | {{tp|p=32553757|t=2020. Aminosalicylates and COVID-19: Facts or Coincidences?|pdf=|usr=010}} | ||
| + | {{tp|p=32530870|t=2020. Rapid Review: Nonsteroidal Anti-inflammatory Agents and Aminosalicylates in COVID-19 Infections.|pdf=|usr=011}} | ||
| Zeile 38: | Zeile 44: | ||
{{tp|p=32354685|t=ä. Why choose cyclosporin A as first-line therapy in COVID-19 pneumonia |pdf=|usr=}} | {{tp|p=32354685|t=ä. Why choose cyclosporin A as first-line therapy in COVID-19 pneumonia |pdf=|usr=}} | ||
{{tp|p=32487139|t=2020. Cyclosporine A: a valid candidate to treat COVID-19 patients with acute respiratory failure?|pdf=|usr=011}} | {{tp|p=32487139|t=2020. Cyclosporine A: a valid candidate to treat COVID-19 patients with acute respiratory failure?|pdf=|usr=011}} | ||
| + | {{tp|p=32415310|t=2020. Cyclosporine therapy in cytokine storm due to coronavirus disease 2019 (COVID-19).|pdf=|usr=009}} | ||
Aktuelle Version vom 18. Januar 2021, 20:51 Uhr
| PHA Biologicals |
Dapsone
32344275 2020. Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS)
32339778 ä. Dapsone and Doxycycline could be potential treatment modalities for COVID-19
31931639 2020. Dapsone as treatment adjunct in ARDS
Cyclophosphamide
32526511 2020. A potential role for cyclophosphamide in the mitigation of acute respiratory distress syndrome among patients with SARS-CoV-2.
Aminosalicylates
32553757 2020. Aminosalicylates and COVID-19: Facts or Coincidences?
32530870 2020. Rapid Review: Nonsteroidal Anti-inflammatory Agents and Aminosalicylates in COVID-19 Infections.
Thiopurines azathioprin
32400020 2020. COVID-19 and implications for thiopurine use.
MMF mycophenolic acid
32579258 2020. Antiviral activities of mycophenolic acid and IMD-0354 against SARS-CoV-2.
mTOR ihibitors rapamycin
32313883 2020. Inhaled biguanides and mTOR inhibition for influenza and coronavirus (Review)
32334502 2020. The Mechanistic Target of Rapamycin (mTOR): Novel Considerations as an Antiviral Treatment
32410266 2020. Immunoregulation with mTOR inhibitors to prevent COVID-19 severity: A novel intervention strategy beyond vaccines and specific antiviral medicines.
32413699 2020. Lithium chloride combination with rapamycin for the treatment of COVID-19 pneumonia.
32578354 2020. Obesity and COVID-19: The mTOR pathway as a possible culprit.
32405269 2020. Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19.
32574238 2020. An Open Question: Is It Rational to Inhibit the mTor-Dependent Pathway as COVID-19 Therapy?
Calcineurin inhibitors
32603679 2020. Calcineurin inhibitors revisited: A new paradigm for COVID-19?
Cyclophilin A inhibitors
32347055 2020. Role of cyclophilin A during coronavirus replication and the antiviral activities of its inhibitors
Alisporivir
| 32376613 2020. Inhibition of SARS-CoV-2 infection by the cyclophilin inhibitor Alisporivir (Debio 025) |
32409832 2020. SARS-CoV-2 pandemic : Time to revive the cyclophilin inhibitor alisporivir.
Cyclosporin A
32354685 ä. Why choose cyclosporin A as first-line therapy in COVID-19 pneumonia
32487139 2020. Cyclosporine A: a valid candidate to treat COVID-19 patients with acute respiratory failure?
32415310 2020. Cyclosporine therapy in cytokine storm due to coronavirus disease 2019 (COVID-19).
